Obsidian (OBX) Director Heidi Hagen Receives Award of 37,653 Shares

What Happened

• Heidi Hagen, a director of Obsidian Therapeutics (OBX), received a derivative award covering 37,653 shares on 2026-08-03. The Form 4 reports an acquisition amount of $0.00 for the award (derivative instrument rather than an open‑market purchase).

Key Details

• Transaction date: 2026-08-03; reported on Form 4 (accession 0001193125-26-335055) filed 2026-08-05.
• Instrument: derivative award (37,653 shares) reported at $0.00 acquisition price.
• Vesting/exercisability: The shares underlying the option vests and becomes exercisable on the earlier of (i) the one‑year anniversary of the grant or (ii) the issuer's next annual meeting, subject to Hagen’s continued service (per footnote).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Timeliness: Filing appears timely (reported two business days after the transaction); no late filing indicated.

Context

• This was a grant/award of a derivative instrument (likely stock options or RSUs as described); it is not an open‑market purchase or sale, and does not necessarily signal immediate buying or selling intent. The award vests based on time/continued service, so holdings are contingent until vesting/exercisability.